Abstract: The possibility that hypothermia started during or after resuscitation at birth might reduce brain damage and cerebral palsy has tantalized clinicians for a long time. The key insight was that transient severe hypoxia-ischemia can precipitate a complex biochemical cascade leading to delayed neuronal loss. There is now strong experimental and clinical evidence that mild to moderate cooling can interrupt this cascade, and improve the number of infants surviving without disability in the medium term. The key remaining issues are to finding better ways of identifying babies who are most likely to benefit, to define the optimal mode and conditions of hypothermia and to find ways to further improve the effectiveness of treatment.
Introduction
The possibility that mild cooling might reduce the severe disability associated with moderate to severe acute neonatal encephalopathy has tantalized clinicians for over 300 years. 1 The first direct experimental studies showed that cooling perinatal rodents greatly extended the ''time to last gasp'' during hypoxia and improved subsequent functional outcomes. In retrospect, this and many subsequent studies did not directly address whether hypothermia started after hypoxia was protective, but these encouraging data led to uncontrolled case series in the 1950s and 1960s, in which infants who were not breathing spontaneously at 5 minutes after birth were immersed in cold water until respiration resumed and then allowed to slowly spontaneously rewarm. 2 Outcomes after cooling at birth were reported to be better than for historical controls. Although these studies preceded the development of active resuscitation, immersion cooling was able to be combined with positive pressure resuscitation. 3 These provocative studies were not followed up at the time because of the recognition that mild hypothermia was associated with increased oxygen requirements and greater mortality in premature newborns (<1500 g), 4 and the disappointing outcome of delayed cooling after near drowning. 5 In the present review, we will briefly examine the scientific advances that led to a resurgence of interest in hypothermia, dissect the clinical evidence that hypothermia is efficacious, and then consider whether hypothermia should be considered for routine clinical practice. We will then discuss potential issues relating to the alternate approaches to using cooling.
Pathophysiology of Delayed Brain Injury
The central observation arising from experimental and clinical studies over the last decade was that hypoxic-ischemic injury can trigger a cascade of events during and after the insult that lead to cell death many hours, or even days later (secondary or delayed cell death). For example, Azzopardi and coworkers 6 showed that infants with evidence of moderate to severe neonatal encephalopathy often have normal cerebral oxidative metabolism on magnetic resonance spectroscopy shortly after birth, but many then went on to develop delayed energy failure 6 to 15 hours later. In survivors, the degree of secondary energy failure after 24 to 48 hours was closely associated with neurodevelopmental outcome at 18 months and 4 years of age. 7 Those infants who had a fixed loss of metabolic activity after birth, without even transient recovery had a very high mortality. 6 An identical pattern of initial recovery of cerebral oxidative metabolism followed by secondary energy failure was seen after hypoxia-ischemia in the piglet, rat, and fetal sheep and was closely correlated to the severity of neuronal injury. [8] [9] [10] [11] On the basis of such studies, distinct phases of developing injury may be discerned, as illustrated in Figure 1 . 12 The period of hypoxia-ischemia is the primary phase of cell injury. During this time high-energy metabolites are depleted, with progressive depolarization of cells, severe cytotoxic edema (cell swelling), extracellular accumulation of excitatory amino acids (EAAs) due to both failure of reuptake by astroglia and excessive depolarization-mediated release. Once the cerebral circulation and/or oxygenation are restored after end of the insult, the initial hypoxia-induced impairments of cerebral oxidative metabolism, cytotoxic edema, and accumulation of EAAs resolve over approximately 30 to 60 minutes. After this there may be a ''latent'' phase, which is followed by a secondary deterioration, starting many hours later (approximately 6 to 15 h) and extending over many days. At term equivalent, this secondary deterioration is often marked by delayed seizures, 13 secondary cytotoxic edema (cell swelling), accumulation of excitotoxins, failure of cerebral mitochondrial activity, 8, 11 and ultimately, cell death. 12 These concepts are of immediate importance for understanding when hypothermia works.
HOW LATE IS TOO LATE?
There is now overwhelming evidence that the latent phase before the start of the secondary deterioration represents the effective window of opportunity for starting cooling. For example, in the near-term fetal sheep, moderate hypothermia induced 90 minutes after reperfusion from a severe episode of cerebral ischemia, in the early latent phase, and continued until 72 hours after ischemia, prevented secondary cytotoxic edema, and improved electroencephalographic recovery. 13 There was a concomitant substantial reduction in cortical infarction and improvement in neuronal loss scores in all regions. When the start of hypothermia was delayed until just before the onset of secondary seizures in this paradigm (5.5 h after reperfusion) partial neuroprotection was seen.
14 With further delay until after seizures were established (8.5 h after reperfusion), there was no electrophysiologic or overall histologic protection with cooling. 15 Other studies strongly support this relationship. For example, in unanesthetized infant rats subjected to moderate hypoxia-ischemia mild hypothermia (2 to 31C decrease in brain temperature) for 72 hours from the end of hypoxia prevented cortical infarction, whereas 6 hours of cooling had an intermediate effect. 16 Similarly, in anesthetized piglets exposed to either hypoxia with bilateral carotid ligation or to hypoxia with hypotension, either 12 hours of mild whole body hypothermia (351C) or 24 hours of head cooling with mild systemic hypothermia started immediately after hypoxia prevented delayed energy failure, 17 reduced neuronal loss, 18, 19 and suppressed posthypoxic seizures. 19 
HOW LONG IS ENOUGH?
These and other data suggest that it would be highly desirable to start cooling immediately after birth (presuming that this terminates the exposure to hypoxia). At present though this is impractical because the majority of infants requiring During reperfusion after the insult, there is a period of approximately 30 to 60 minutes during which cellular energy metabolism is restored, with progressive resolution of the acute cell swelling secondary to hypoxic-depolarization. This is followed by a latent phase, during which oxidative metabolism has normalized, but there is hyperactivity of glutaminergic receptors, the intracytoplasmic components of the apoptotic cascade are activated and the secondary inflammatory reaction is initiated. This may be followed by secondary deterioration leading to ultimate delayed neuronal death after 3 days. As indicated by the bar, treatment with cerebral hypothermia needs to be initiated as early as possible in the latent phase before the onset of secondary deterioration, and then continued for over 48 hours for long lasting neuroprotection.
resuscitation or with metabolic acidosis on cord blood do not go on to develop hypoxic-ischemic encephalopathy (HIE). 20 By the time that encephalopathy can be reliably diagnosed, many hours have passed. The experimental literature strongly suggests that when hypothermia is delayed a relatively prolonged interval of cooling is required for significant protection.
As previously noted, mild hypothermia (2 to 41C reduction in temperature) for a few hours was partially protective when started immediately after hypoxia-ischemia in piglets, and neonatal rats, but not when cooling was delayed just 15 to 45 minutes after the primary insult. 12 These results are consistent with the finding in adult gerbils that when the delay after cerebral ischemia before initiating a 24-hour period of cooling was increased from 1 to 4 hours, neuroprotection in the CA1 region of the hippocampus after 6 months recovery fell from 70% to 12%. 21 This chronic loss could be prevented by extending the duration of moderate (32 to 341C ) hypothermia to 48 hours plus, even when the start of cooling was delayed until 6 hours after reperfusion. 22, 23 HOW COLD DO PATIENTS NEED TO BE KEPT?
The precise ''dose response'' of therapeutic hypothermia for babies is still unclear. Overall, experimental studies suggest that a reduction of 3 to 51C (ie, core temperature of 32 to 341C) is likely to be most effective. There is good evidence for a threshold effect after severe insults. In fetal sheep cooled from 90 minutes after ischemia, substantial neuroprotection was seen only in fetuses in whom there was a sustained decrease in the extradural temperature to <341C (normal temperature in the fetal sheep is 39.51C). 13 Further, in adult gerbils, cooling to a rectal temperature of 321C was associated with greater behavioral and histologic neuroprotection than 341C. 24 It is critical to appreciate that although there is little information from perinatal models on deeper cooling, there is much greater potential for severe adverse systemic effects below core temperatures of approximately 30 to 331C. 25 Consistent with this concern, in adult dogs deep hypothermia (core temperature of 151C) after cardiac arrest was associated with worse neurologic outcomes than normothermia, whereas mild hypothermia (34 to 361C), from 10 minutes until 12 hours after cardiac arrest was beneficial. 26 
IS NEUROPROTECTION SUSTAINED?
There have been reports that hypothermia only delayed, rather than prevented, neuronal degeneration after global ischemia in the adult rat 27, 28 and hypoxia-ischemia in the 7-day old rat. 29 These studies used relatively short intervals of hypothermia (3 to 5 h). In contrast, cooling to 51C for 6 hours 30 or 72 hours of very mild cooling in infant rats were associated with long-term improvement after carotid occlusion and hypoxia. 16 Thus, the most likely explanation is that the duration and/or degree of hypothermia were insufficient. Further, late hyperthermia can compromise the benefits of early cooling; in a study in adult rats a combination of early hypothermia plus prevention of spontaneous delayed pyrexia with antipyretics was associated with histologic protection after 2 months recovery. 28 Subsequent studies both in the 7-day rat and in adult species have confirmed that a sufficiently prolonged phase of moderate cooling can be associated with persistent behavioral and histologic protection for many weeks and months. [22] [23] [24] [30] [31] [32] [33] 
MECHANISMS OF ACTION
The precise mechanisms of hypothermic neuroprotection are not fully understood. Exposure to oxygen-free radical toxicity, and excessive levels of EAAs (so-called excitotoxicity) during hypoxia-ischemia and consequent intracellular calcium accumulation, 34 are major initial triggers of the cascade leading to delayed cell death, but rapidly resolve during reperfusion from the insult and thus cannot readily be related to the effect of delayed cooling. It is striking that in vitro neuronal degeneration can be prevented by cooling initiated well after exposure to an insult. 35 Thus, the critical effect of hypothermia must be on secondary consequences, such as the intracellular progression of programmed cell death (apoptosis), the inflammatory reaction, and abnormal receptor activity.
PROGRAMMED CELL DEATH
There is good histologic evidence that programmed cell death is a significant contributor to posthypoxic cell death in the developing human brain. 12 Consistent with this, hypothermia started after severe hypoxia-ischemia was reported to reduce apoptotic cell death, but not necrotic cell death in the piglet. 18 Although multiple pathways are likely to be involved in postischemic programmed cell death, caspase-3, one of the family of cysteine proteases, is one of the major ''downstream'' mechanisms. Consistent with the suggestion that these pathways are important therapeutic targets, protection with postischemic hypothermia in the near-term fetal sheep was close linked with suppression of activated caspase-3. 36 
INFLAMMATORY SECOND MESSENGERS
Brain injury leads to induction of the inflammatory cascade with increased release of cytokines and interleukins (ILs). 37 These compounds are believed to exacerbate delayed injury, whether by direct neurotoxicity and induction of apoptosis or by promoting stimulation of leukocyte adhesion and infiltration into the ischemic brain. Experimentally, cooling potently suppresses this inflammatory reaction. 12 For example, in vitro, hypothermia inhibits proliferation, superoxide and NO production by cultured microglia, and in adult rats hypothermia suppresses the posttraumatic release of IL-1b, and accumulation of polymorphonuclear leukocytes. Similarly, postischemic hypothermia can suppress microglial activation after transient ischemia in the fetal sheep. 36 
EXCITOTOXITY AFTER HYPOXIA-ISCHEMIA
Classically, cell death due to abnormal glutamate receptor activation (excitotoxicity) is related to pathologically elevated levels of extracellular glutamate, as occurs during hypoxia-ischemia. After reperfusion, we and others have shown that glutamate levels rapidly return to control values, 12 and thus naively we might predict that excitotoxicity should not be important after reperfusion. More recent data, however, show that pathologic hyperexcitability of glutamate receptors can continue for many hours after hypoxiaischemia and that receptor blockade can suppress this activity and improve neuronal outcome. 38 Although it is still unknown whether hypothermia affects this abnormal posthypoxic receptor activity there are recent data that hypothermic protection is linked with suppression of abnormal neuronal activity in the early recovery phase, 39 whereas it has little effect on delayed overt seizures, 13, 39 supporting the hypothesis that suppression of abnormal receptor function in the early recovery phase may be a significant mechanism of protection.
Clinical Evidence

FEASIBILITY AND SAFETY STUDIES
The first small controlled trials of head cooling with mild hypothermia [40] [41] [42] [43] and of whole body cooling 44 in asphyxiated newborns, were designed around the experimental evidence discussed above on when and how hypothermia can be protective. These studies confirmed that it was feasible to induce hypothermia even in very sick newborns, without any apparent increase in major adverse events. These data have been supported by several case series. [45] [46] [47] The first studies focused on head cooling plus incremental increases in the degree of mild systemic hypothermia, [40] [41] [42] [43] because of concerns about the safety of systemic hypothermia. However, once this had been demonstrated to be safe other studies evaluated systemic hypothermia alone at levels intended to achieve comparable reductions in brain temperature. The issue of whether these approaches have different outcomes is discussed below.
Although none of these early studies were powered to evaluate neurologic outcome, the results were encouraging. 41, 48, 49 For example, in a controlled study of head cooling, of 24 infants with stage II or III encephalopathy in the first 6 hours of life, hypothermia was associated with a trend to reduced cerebral palsy in survivors compared with normothermia [odds ratio (OR) 0.46, 95% confidence interval (CI) 0.08, 2.56]. 41 A retrospective study of whole body cooling to between 32 and 341C in 10 infants found a significant reduction of major neurologic abnormalities and abnormal magnetic resonance imaging findings at follow up compared with 11 historical controls. 48 A larger randomized pilot study of head cooling with mild hypothermia compared with normothermia found a significant reduction in neuron-specific enolase levels in cerebral spinal fluid with cooling but only a small increase in normal developmental outcome at 6 months of age in 18 of 23 cooled patients (78.3%) compared with 19 of 27 (70.4%) normothermic infants. 49 
HEAD COOLING
The first large multicenter randomized controlled study of hypothermia for HIE was the CoolCap trial. 50 In this study, term infants with moderate to severe HIE on the basis of sequential neurologic examination and electrophysiologic monitoring were randomized to head cooling with mild systemic hypothermia to rectal temperatures of 34 to 351C (n = 116), or to conventional care (n = 118). Cooling was associated with a borderline reduction in the rate of death or severe disability at 18 months; adjusted for the baseline electrographic changes, OR 0.57, 95% CI 0.32-1.01, P = 0.05. We note that 4 patients randomized to cooling were not cooled, for various reasons, including 2 because of interpretation of the randomization card. A secondary, per-treatment analysis excluding these 4 patients suggests a significant effect of cooling; OR 0.48, 95% CI 0.26, 0.90, P = 0.02. No increase in major adverse events was found, as discussed further below.
The borderline effect of cerebral hypothermia in this trial was arguably, in part, a reflection of an apparent imbalance in initial randomization, with more infants with stage III HIE and very low Apgar scores in the hypothermia group. A secondary analysis controlling for the effect of severity of HIE suggested a significant overall effect of hypothermia: OR 0.55, 95% CI 0.31-0.98, P = 0.042. 51 Alternatively, it may have reflected inclusion of infants with relatively severe or more advanced encephalopathy. Consistent with this, a preplanned subgroup analysis suggested that adverse primary outcome was reduced by hypothermia in infants with less severe electroencephalographic changes at trial entry (n = 172, OR 0.42, 95% CI 0.22-0.80, P = 0.009). 50 In contrast, however, there was no benefit in those with the combination of seizures and profound suppression of the amplitude integrated electroencephalogram (aEEG) recording before cooling was started (n = 46, OR 1.8, 95% CI 0.49-6.4, P = 0.51). The observation that the control patients in each of these subgroups defined by these aEEG criteria had very similar long-term outcomes suggests that the different responses to hypothermia may have been a reflection of timing of injury. That is to say, that the severe group may have had brain injury earlier before birth, and so already progressed into the secondary phase at the time of the initiation of cooling. 50 The improved outcome of infants in the larger, more mildly affected group defined on aEEG criteria was primarily due to a reduction in motor disability, with a more than 50% reduction in severe neuromotor disability in survivors and improved continuous BSID-II scores. In contrast, there was no overall change in early neonatal mortality (27 cooled vs. 26 control cases in the full study group), and a small apparent reduction in late mortality (9 vs. 16 cases, respectively). Although this is not a large category, the difference in late events is intriguing because the great majority of late deaths in both groups were related to complications of severe disability.
A subsequent, post-hoc subgroup analysis suggested an effect of birth-weight. There was a highly significant cooling effect in the infants with weight above the 25th percentile, with unfavorable primary outcome in 35/69 (51%) cooled infants versus 59/77 (77%) control infants, P = 0.002. In contrast, infants below the 25th percentile for weight showed no apparent treatment effect [24/39 (62%) vs. 14/33 (42%), P = 0.16]. 51 The significance of this intriguing and unexpected finding is unclear. In part, it was probably related to a small increase in the risk of pyrexia with increasing birth weight among control infants; experimentally, pyrexia is well established to worsen brain injury. 12 However, the adverse effect of greater birth weight in control infants remained significant after adjustment for pyrexia and severity of encephalopathy. Alternatively, it may suggest a different profile of antecedent perinatal events in larger and smaller infants, leading to a different timing of secondary damage.
WHOLE BODY COOLING
In a second large multicenter trial Shankaran and colleagues 52 examined the effect of whole body cooling in 208 infants with clinical and laboratory criteria suggesting exposure to severe perinatal hypoxia and who had moderate or severe HIE on neurologic examination by trained examiners. Infants in the experimental group (n = 102) were placed on a cooling blanket and cooled to a rectal temperature of 33.5 ± 0.51C for 72 hours. After 18 months of follow up, the incidence of death and/or moderate-to-severe disability was significantly reduced in the cooled infants (45%) compared with the normothermic group [62%, relative risk (RR) 0.72; 95% CI, 0.55-0.93]. No significant adverse effects of hypothermia were seen.
Finally, a smaller randomized clinical trial examined the effect of whole body cooling to a rectal temperature of 331C for 48 hours, initiated within 6 hours of birth, in 65 infants with evidence of HIE. In contrast with the previous studies the somewhat deeper central cooling in this study was associated with some adverse effects although these were clinically manageable, including longer dependence on inotropic agents, prolongation of prothrombin times, and lower platelet counts with more patients requiring plasma and platelet transfusions. 53 However, the combined outcome of death or severe motor scores at 12 months was significantly reduced in the hypothermia group (52%) compared with thenormothermiagroup(84%)(P=0.019). 54 Severely abnormal motor scores were recorded in 64% of normothermia patients and in 24% of hypothermia patients. Further trials of whole body cooling are still in progress, including the Total Body Cooling trial (TOBY) in England, the NeoNetwork trial in central Europe and the Infant Cooling Evaluation (ICE) trial in Western Australia. 55 
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JUST HOW SAFE IS COOLING IN INFANTS WITH HIE?
The studies discussed above suggested that mild hypothermia is generally safe. For example, the only consistent minor adverse effect of head cooling was scalp edema under the cap, which resolved rapidly before or after removal of the cap. Nevertheless, they have also highlighted the critical importance of understanding the physiologic changes associated with cooling, and for this reason we do not believe that at present hypothermia should be used outside of intensive care environments. 25 Given that HIE is, fortunately, relatively uncommon in developed countries, it is likely that treatment will often be initiated by relatively inexperienced staff. We are aware that episodes of uncontrolled hypothermia during transport of very ill infants before admission have already occurred. A cycle of cooling, warming, and cooling is likely to be bad-rapid warming has been associated with cardiovascular instability in at least a few cases 45 and may have adverse cerebral effects. 56 Thus, it is vital that training should also encompass appropriate outborn and transport management.
The head cooling system is specifically designed to limit the degree of whole body hypothermia and thus the potential for adverse systemic effects. On the other hand, whole body cooling is much easier to apply either in remote sites or during transport, and so would allow earlier initiation of therapy in outborn infants. 57 Thus, we may speculate that an ideal protocol might involve initial systemic hypothermia applied as soon as possible by protocol at the remote site, and during transport, followed by selective head cooling in intensive care, without rewarming in the interim.
Potential issues that attending pediatricians should be aware of during hypothermia include suppression of immune function, prolongation of clotting times, metabolic effects, and cardiovascular adaptation during cooling. In particular, although there was no increase in the rate of infection in cooled newborn infants, it is important to appreciate that these trials included both routine screening and treatment for possible perinatal infection, 50, 52 and that a few infants in both studies did have evidence of septicemia at enrollment. Hypothermia has profound immune suppressive and anti-inflammatory effects and in older adults is associated with increased risk of infective complications such as pneumonia and bacteremia, 25 and thus this potential risk must continue to be carefully managed in all patients.
Further, as noted above, although no increase in hemorrhagic complications was reported in either of the 2 large randomized trials, 50, 52 the smaller study from Eicher et al 53 did suggest such an increase. It is unclear at this time whether this is a specific concern with the choice of a lower target temperatures in that trial (331C), or simply a chance finding. It is reassuring that in piglet studies where the cortex was cooled significantly (to <301C) no hemorrhagic changes were seen in the brain. 58 Hypothermia is consistently associated with transient mild hyperglycemia, both in adult 59 and newly born trials, 50 likely reflecting hypothermia-induced catecholamine release, but no increase in the risk of hypoglycemia. 50, 52 For example, in the CoolCap study transient hyperglycemia was found from 4 to 24 hours compared with controls (mean ± SD, 7.6 ± 4.4 vs. 5.4 ± 3.1 mmol/L, at 4 h), 50 which resolved spontaneously. This is consistent with the effects of hypothermia in piglets and near-term fetal sheep. 13, 60 It is important to note that in piglets as cooling was continued, increased glucose administration became necessary to maintain normal levels. 60 Conversely, it is interesting to note that in the CoolCap trial there was an apparent reduction in the incidence of elevated liver enzymes in the cooled group (38% of cooled infants vs. 53% of controls, P = 0.02), raising the possibility that induced hypothermia may have benefits for some systems outside the brain.
Hypothermia slows the atrial pacemaker and intracardiac conduction, and thus is consistently associated with mild, sustained sinus bradycardia. 50, 52 This linear relation between heart rate and core temperature likely partly reflects the increased metabolic need with increasing temperature, and thus this physiologic effect per se does not require any treatment. In addition, initiation of cooling is reported to be associated with a small, transient increase in blood pressure both experimentally 12 and clinically. 45 This response is mediated by peripheral vasoconstriction, that is, thermal centralization of blood flow. At present it is unclear whether this has clinically important consequences, but clinicians should be aware of the phenomenon. Further, during cooling, a few infants show markedly prolongation of the QT interval of the infants' EKG to above the 98th percentile corrected for age and heart rate, without arrhythmia. These changes resolve with rewarming. 61 Although such prolonged QT in the absence of ventricular arrhythmia may be safe, close monitoring is clearly essential and other therapies which lengthen the QT interval (such as macrolide antibiotics) should be avoided.
SUMMARY OF CLINICAL STUDIES
Taken together, the remarkably similar effect sizes in 2 large and 1 smaller randomized controlled trials strongly suggest that induced hypothermia is associated with a significant reduction in death or disability. As reported in a recent metaanalysis, 62 the overall rate of death or disability in the 3 largest studies was 118 of 237 patients treated with hypothermia compared with 158 of 241 normothermic patients, giving a RR of 0.76 (0.65-0.89), P = 0.001, that is, a 24% reduction in risk, with a number needed to treat of 6.
Potentially, relatively greater improvements may be able to be obtained if we can target therapy more effectively, as suggested by the CoolCap trial. 50 Should Hypothermia be Used as an Investigational Protocol Only?
The central issue now is whether we should wait for other trials to complete before concluding that hypothermia is partially beneficial? We would argue that although many additional questions need to be answered about how hypothermia should be used, as summarized in a recent National Institute of Child Health and Human Development workshop, 55 its basic efficacy is now solidly established. Even if at one extreme, there was no apparent effect of cooling among the next 400 children to be randomized, then the cumulative meta-analysis would continue to show a significant overall effect, RR 0.85, 95% CI 0.76-0.96, P = 0.01. Thus, the consolidated finding that hypothermia can significantly, and safely, improve the medium term outcome from moderate to severe HIE is highly robust.
Further, our confidence in this conclusion may be strengthened by looking to see whether the treatment is also beneficial in related clinical conditions. Two large randomized controlled trials have also shown that induced cooling is protective in adult patients with profound hypoxic encephalopathy after cardiac arrest. 59, 63 Given that no other therapy for HIE is available or is even ready to test in large studies, the authors suggest that it is now reasonable and appropriate for individual clinicians and centers to use therapeutic hypothermia, provided that they recognize the many uncertainties that surround its optimal use, are familiar with its known physiologic and potential adverse effects, and adhere to one of the cooling protocols that has been established in the large randomized trials. 55 Indeed, provided that rigorous selection criteria are used, 55 it may well be argued that it is now unethical to withhold treatment from infants with HIE when the alternative is a higher probability of life-long disability or death.
Outstanding Clinical Questions
HOW LATE IS REALLY TOO LATE?
The real clinical window of opportunity for treatment with hypothermia, or any other putative therapy, is simply not clear. It is important to appreciate an inherent aspect of all experimental treatment studies. They used very carefully standardized insults, occurring at a precisely known time. In contrast, the precipitating insult in neonatal encephalopathy is a well defined event, such as placental abruption that is terminated at birth, in only approximately 25% of cases. 64 In other cases, the preceding insults seems to evolve over hours during labor, and in at least some cases, perhaps 10% of the total, the infant seems to have been compromised even before labor started. 64 Thus, it seems very likely that the effective window of opportunity to treat HIE will, in some cases, be somewhat less than suggested experimentally. As mild cooling does not significantly suppress aEEG activity it may be that in the future it will be possible to initiate therapy more rapidly (particularly for outborn infants) by delaying electrophysiologic evaluation after cooling has been started and then either continuing or withdrawing therapy once this information is available. The existing clinical trials were unable to determine the duration of the clinical window of opportunity as too few infants were able to start treatment early after birth; just 12% of infants were able to start treatment before 4 hours in the CoolCap trial for example. 50 Nevertheless, given that mild cooling has not been associated with any obvious harm to babies, it could be argued that a liberal interpretation of this window is reasonable while waiting for more data to become available.
CAN WE BETTER SELECT PATIENTS WHO ARE LIKELY TO BENEFIT?
It is clear from the multicenter trials reported to date that neuroprotection with hypothermia as currently used is only partial, such that many patients die of neural injury or survive with disability despite hypothermia. 50, 59, 63 A similar range of outcomes is seen after hypothermia for adult comatose cardiac arrest. 59, 63 The fundamental biology indicates that it is inevitable that we will never be able to rescue the brains of all infants with HIE. As discussed earlier, some infants with severe HIE simply did not show any initial recovery of cerebral oxidative metabolism, and had extremely poor outcomes, typically death. 6 Further, we must also recognize that the speed of evolution of delayed cell death is in large part a function of severity of injury. More severe insults are associated with much more rapid progression of delayed neuronal loss, and as previously noted, are associated with corresponding reduced effectiveness of therapy. 12 Thus, it is possible that one reason for the limited response in the 2 multicenter trials may have been that the trials recruited many infants whose encephalopathy was either too severe to treat or had already entered the secondary deterioration phase at the time of recruitment.
Ideally, we would like to identify the potentially treatable cases in advance, to avoid offering false hope, and to target treatment to those who are most likely to benefit. Clinical evaluation of the severity of HIE, using criteria modified from Sarnat and Sarnat, was highly predictive of the risk of death or disability in both trials. Despite this, strikingly, and contrary to the authors' and many others' expectations at the time that the trials were developed, the relative improvement was remarkably similar for infants with moderate (stage II, RR 0.79, 95% CI 0.57-1.11) and severe (stage III, RR 0.77 95% CI 0.67-0.96) HIE. 65 Similar results were found after whole body cooling. 52 Thus, despite its prognostic reliability clinical evaluation does not seem to distinguish between ''treatable'' and ''untreatable'' cases in the first 6 hours after birth.
In contrast, the CoolCap trial suggested that EEG monitoring could identify a subgroup of infants with profound suppression of amplitude and onset of seizures at the time of randomization who did not respond. 50 Although these findings are extremely suggestive, given that the CoolCap study was the first and to date only trial to use aEEG monitoring for this purpose the authors believe that it is premature to use this or any other parameter to identify infants who are ''too severe'' to treat, until the findings have been replicated by several studies. More data may be expected from the ongoing TOBY trial. Similarly, the criteria of Sarnat and Sarnat were developed many decades ago, and are based on assessment of infants who are more than 24 hours old, before the therapeutic era. It is likely that focused clinical and animal studies will be able to identify components of clinical examination, biochemical tests, or of EEG recordings that might be more predictive of the timing (as opposed to severity) of HIE and of the response to cooling.
IS HEAD COOLING BETTER THAN WHOLE BODY COOLING?
To provide adequate neuroprotection with minimal risk of systemic adverse effects in sick, unstable neonates, ideally only the brain would be cooled. Although this can be achieved in piglets, 58 who have relatively smaller heads, this is impractical in babies. As the CoolCap study demonstrates, partially selective cerebral cooling can be obtained using a cooling cap applied to the scalp, while the body is warmed by an overhead heater to limit the degree of systemic hypothermia. 40, 42, 66 Mild systemic hypothermia (34 to 351C) is still desirable during head cooling, firstly to reduce the steepness of the intracerebral gradient which develops during true selective head cooling, 67 to avoid excessively cold cap temperatures which might cause scalp injury or exacerbate local scalp edema, 42 and to provide some cooling of deep cerebral structures such as the brain stem. Head cooling has recently been demonstrated in the piglet to be associated with a substantial (median 5.31C), sustained decrease in deep intracerebral temperature at the level of the basal ganglia compared with the rectal temperature. 68 Although direct temperature measurements are not yet available in infants, head cooling has been shown to increase the gradient between nasopharyngeal and rectal temperature by approximately 11C in asphyxiated newborns. 40 It is not possible to tell from the recent trials whether it is more or less effective than whole body cooling; as described above the overall effect sizes were extremely similar. 50, 52 Intriguingly, recent short-term recovery studies in the piglet suggest that the optimal degree of cooling needed for neuroprotection may be greater in the cortex than in the basal ganglia. 69 Given that during whole body cooling of the piglet there was <0.61C difference between the warmest (basal ganglia) and the coldest parts of the brain (the cortex), whereas during head cooling there was an approximately 61C gradient between the superficial and deep brain, 58 it is possible that head cooling may provide a more effective balance of cooling to these structure than whole body cooling, and thus provide a relatively better protective effect in the cortex, with better preservation of cognitive function.
Supporting this experimental observation, a recent case series found that head cooling but not whole body cooling was associated with a reduction in the incidence of severe cortical lesions, 70 as examined by magnetic resonance imaging. Interestingly, in that report, both head and whole body cooling were associated with a decrease in basal ganglia and thalamic lesions that was significant in infants with moderate aEEG changes but not in those with severe aEEG findings. 70 These preliminary findings suggest the possibility that long-term follow up of the CoolCap study may show a relatively greater effect on cognitive than motor ability compared with whole body cooling.
HOW MUCH SHOULD WE COOL?
This is one area where the clinical studies did not closely follow the experimental evidence. As reviewed above, overall the evidence suggests that 51C of cooling (corresponding with a rectal temperature of 321C in humans) is better than a reduction of 31C (ie, equivalent to 341C). 12 The trials of whole body, however, used a target rectal temperature of around 33.51C. Although mild to moderate cooling in an intensive care environment has been impressively safe, some clinical side effects have been suggested by studies using lower temperatures. 53 This suggests that at present we are targeting the upper half of the ideal range, and that slightly more cooling, at least for a time, might allow still greater cerebral protection. The reason for this discrepancy is of course that the clinicians designing the studies were highly concerned not to cause side effects in these unstable infants. Only large clinical trials can resolve whether slightly deeper systemic cooling (ie, 32 to 331C) is better or worse than the current target ranges. It may well be that, as speculated above, head cooling may provide such deeper cooling of the cortex, although not other brain structures.
WHERE TO NEXT?
Formidable practical problems face us when we try to answer the outstanding clinical questions such as those listed above. 55 In particular, it is simply unknown whether the 2 modes of therapy are associated with clinically significant long-term differences, whether for example better cortical cooling with head cooling will result in better cognitive outcomes or whether more consistent brainstem cooling with the whole body approach will be associated with reduced neuromotor dysfunction. Although follow up of these studies is vital, it is critical to appreciate that the present studies were powered to examine death or disability at 18 months, not these more subtle long-term outcomes, and thus it is unlikely that they can definitively resolve this question.
More generally, given the small effect sizes that may be anticipated, direct head to head comparison trials of different parameters of cooling treatment must require exponentially more patients than the present studies, and thus will be largely impractical. This creates a serious conundrum for physicianscientists and neonatalogists who are seeking ways to optimize therapy. We propose that all level 3 nurseries should now adopt one of the validated protocols for the selection of term infants with HIE and train staff and be equipped to offer hypothermia by one of the two well described approaches. 55 Given the limitations for future formal trials, it is vital that strict protocols including universal follow up should be adhered to. This will allow consortia of units to examine incremental modifications to the treatment protocols such as the length or degree of hypothermia, allowing progressive refinement of techniques and improvements in outcome analogous to the strategy used to develop pediatric cancer therapy.
Advances in Therapeutic Hypothermia
Conclusions
There is now overwhelming clinical and experimental evidence that mild cerebral cooling in infants with acute HIE can improve medium-term neurologic recovery in a significant subset of infants. The key therapeutic requirements for neuroprotection are that hypothermia is initiated as soon as possible in the latent phase, before secondary deterioration, and continued for a sufficient period in relation to the evolution of delayed encephalopathic processes, typically 48 hours or more.
The long-term effects, at school age and later, are not yet known, and we are only beginning to understand how best to use hypothermia. The immediate question for practicing clinicians is whether they may now cautiously use this first ever treatment for neonatal encephalopathy, while they wait for the questions around its optimal use to be answered? It is the personal view of the authors that given the evidence for benefit from 2 large well conducted randomized controlled trials and a number of smaller studies, the remarkable safety profile, the strong foundation in basic science and supporting evidence from related disease states such as encephalopathy after cardiac arrest, the answer now is yes.
